NEW YORK, NY / ACCESSWIRE / September 5, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Eagle Bancorp, Inc. (EGBN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/eagle-bancorp-inc-loss-submission-form?prid=3364&wire=1
Lead Plaintiff Deadline: September 23, 2019
Class Period: March 2, 2015 to July 17, 2019
Allegations against EGBN include that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
NetApp, Inc. (NTAP)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/netapp-inc-loss-submission-form?prid=3364&wire=1
Lead Plaintiff Deadline: October 15, 2019
Class Period: May 22, 2019 to August 1, 2019
Allegations against NTAP include that: (1) the Company was unable to close large deals within the quarter and that the deals were pushed out to subsequent quarters or downsized; (2) as a result, the Company’s revenue would be materially impacted; (3) as a result, the Company would lower its fiscal 2020 guidance; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Sarepta Therapeutics, Inc. (SRPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?prid=3364&wire=1
Lead Plaintiff Deadline: October 29, 2019
Class Period: September 6, 2017 to August 19, 2019
Allegations against SRPT include that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen’s accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: